CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, Unlocking New Revenue Channels & Strategic Growth Opportunities
CBD Life Sciences (OTC:CBDL) has signed a Letter of Intent (LOI) with a licensed New Jersey dispensary, marking a strategic entry into the East Coast cannabis market. The partnership establishes a unique dual-channel distribution model where CBD Vault's products will be featured in the New Jersey dispensary while the dispensary's products will be sold in CBDL's retail locations.
The company expects this partnership to generate seven-figure annual revenues and serve as a springboard for expansion in the East Coast corridor. The New Jersey cannabis market alone is projected to exceed $2 billion annually by 2026, while the broader U.S. CBD and cannabis sector is forecasted to reach $33 billion by 2030.
CBD Life Sciences (OTC:CBDL) ha firmato una Lettera di Intenti (LOI) con una dispensary autorizzata del New Jersey, segnando un ingresso strategico nel mercato della cannabis della costa Est. La partnership stabilisce un modello di distribuzione a doppio canale in cui i prodotti di CBD Vault saranno presenti nella dispensary, mentre i prodotti della dispensary saranno venduti nelle sedi al dettaglio di CBDL.
La società si aspetta che questa collaborazione genererà fatturato annuo a sette cifre e servirà da trampolino di lancio per l’espansione lungo l’asse della East Coast. Il mercato della cannabis del New Jersey da solo è previsto superare 2 miliardi di dollari all’anno entro il 2026, mentre il settore statunitense più ampio di CBD e cannabis è previsto raggiungere 33 miliardi di dollari entro il 2030.
CBD Life Sciences (OTC:CBDL) ha firmado una Carta de Intención (LOI) con una dispensaria autorizada en New Jersey, marcando una entrada estratégica en el mercado de cannabis de la Costa Este. La alianza establece un modelo de distribución de doble canal donde los productos de CBD Vault estarán en la dispensaria, mientras que los productos de la dispensaria se venderán en los puntos de venta minoristas de CBDL.
La empresa espera que esta asociación genere ingresos anuales de siete cifras y sirva como trampolín para la expansión en el corredor de la Costa Este. El mercado de cannabis de New Jersey por sí solo se proyecta que supere $2 mil millones anuales para 2026, mientras que el sector estadounidense más amplio de CBD y cannabis se prevé alcance $33 mil millones para 2030.
CBD Life Sciences (OTC:CBDL)가 뉴저지주 면허를 보유한 디스펜서리와 LOI(양해각서)를 체결하며 동해안 대마초 시장에 전략적으로 진출했습니다. 이 파트너십은 이중 채널 유통 모델을 수립하여 CBD Vault의 제품은 뉴저지 디스펜서리에서, 디스펜서리의 제품은 CBDL의 소매점에서 판매되게 됩니다.
회사는 본 파트너십이 연간 일곱 자리 매출을 창출할 것으로 예상하며 동부 해안 확장의 발판이 될 것입니다. 단독으로 뉴저지 대마초 시장은 2026년까지 연간 20억 달러를 초과할 것으로 예상되며, 미국 전반의 CBD 및 대마초 시장은 2030년까지 330억 달러에 이를 것으로 전망됩니다.
CBD Life Sciences (OTC:CBDL) a signé une lettre d’intention (LOI) avec une dispensaire agréé du New Jersey, marquant une entrée stratégique sur le marché du cannabis de la côte Est. Le partenariat établit un modèle de distribution à double canal où les produits de CBD Vault seront présents dans la dispensaire, tandis que les produits de la dispensaire seront vendus dans les points de vente au détail de CBDL.
L’entreprise s’attend à ce que ce partenariat génère des revenus annuels à sept chiffres et serve de tremplin pour l’expansion le long du couloir de la côte Est. Le marché du cannabis du New Jersey seul devrait dépasser 2 milliards de dollars par an d’ici 2026, tandis que le secteur plus large des CBD et du cannabis aux États-Unis devrait atteindre 33 milliards de dollars d’ici 2030.
CBD Life Sciences (OTC:CBDL) hat eine Absichtserklärung (LOI) mit einer lizenzierten Dispensary in New Jersey unterzeichnet, was einen strategischen Einstieg in den Cannabis-Markt an der Ostküste markiert. Die Partnerschaft etabliert ein Dual-Channel-Vertriebsmodell, bei dem CBD Vault-Produkte in der New Jersey Dispensary geführt werden, während die Produkte der Dispensary in den Einzelhandelsstandorten von CBDL verkauft werden.
Das Unternehmen erwartet, dass diese Partnerschaft einen umsatzstarken Siebenstelligen Betrag pro Jahr erzielt und als Sprungbrett für die Expansion im Ostküsten-Korridor dient. Der New-Jersey-Cannabis-Markt allein wird voraussichtlich bis 2026 über 2 Milliarden US-Dollar pro Jahr erreichen, während der breitere US-amerikanische CBD- und Cannabismarkt voraussichtlich bis 2030 auf 33 Milliarden US-Dollar steigen wird.
CBD Life Sciences (OTC:CBDL) وقّعت على رسالة نوايا (LOI) مع صيدلية مُرخّصة في نيوجيرسي، مما يمثل دخولاً استراتيجياً إلى سوق القنب في الساحل الشرقي. تقيم الشراكة نموذج توزيع ثنائي القنوات حيث ستظهر منتجات CBD Vault في الصيدلية، في حين ستُباع منتجات الصيدلية في مواقع البيع بالتجزئة التابعة لـ CBDL.
تتوقع الشركة أن تولّد هذه الشراكة إيرادات سنوية من فئة سبعة أرقام وتكون بمثابة منصة انطلاق للتوسع في ممر الساحل الشرقي. كما يتجاوز سوق القنب في نيوجيرسي وحده أكثر من 2 مليار دولار سنوياً بحلول 2026، بينما من المتوقع أن يصل قطاع CBD والقنب الأمريكي الأوسع إلى 33 مليار دولار بحلول 2030.
CBD Life Sciences (OTC:CBDL) 已与新泽西州一家获得许可的药房签署了意向书（LOI），标志着在东海岸大麻市场的战略进入。此次合作确立了一个<双通道分销模式，其中 CBD Vault 的产品将在新泽西药房销售，而药房的产品则会在 CBDL 的零售点销售。
公司预计此合作将带来<七位数的年度收入，并成为在东海岸走廊扩张的跳板。仅新泽西州的大麻市场预计到 2026 年将超过< b>$20 亿美元/年，而美国更广泛的 CBD 与大麻行业预计到 2030 年将达到< b>$330 亿美元。
- Strategic entry into New Jersey's cannabis market projected to reach $2B by 2026
- Expected seven-figure annualized revenues from the partnership
- Two-way distribution model providing dual revenue streams and market exposure
- Potential for multi-state expansion across the East Coast corridor
- Partnership currently only at LOI stage, not a definitive agreement
- Success depends on effective execution of cross-distribution model
- Faces competition in rapidly growing East Coast cannabis market
Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass
SCOTTSDALE, AZ / ACCESS Newswire / September 23, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its wholly owned subsidiary, CBD Vault, is proud to announce that it has entered into a Letter of Intent (LOI) with a licensed dispensary in New Jersey. This powerful agreement represents not just product placement, but a transformational partnership that creates two-way retail visibility, accelerates brand recognition, and opens the door to significant new revenue streams in one of the fastest-growing cannabis markets in the United States.
A Dual-Channel Partnership for Scalable Growth
Unlike conventional wholesale agreements, this LOI establishes a mutually beneficial distribution model. Under the terms, CBD Vault's flagship products - including the Company's industry-leading CBD Pain Relief Cream, Pain Relief Roll-On, 3000mg CBD Tinctures, and Delta-8 Gummies - will secure premium shelf space inside a bustling New Jersey dispensary. In return, select products from the dispensary's proprietary line will be stocked and featured in CBDL's own retail locations, creating a cross-pollination of audiences and expanding market reach for both companies.
This two-way approach not only diversifies CBDL's product mix but also positions the Company as a true collaborative partner within the cannabis ecosystem, enhancing long-term relationships and securing recurring sales channels.
Massive Market Potential on the East Coast
New Jersey's cannabis industry is emerging as a powerhouse. Recent research projects the state's market to surpass
For CBDL, this LOI is more than regional growth - it's an entry point into the lucrative East Coast corridor, which includes high-value markets such as New York, Pennsylvania, and Massachusetts. Establishing a foothold in New Jersey provides an anchor for potential multi-state expansion and positions the Company at the forefront of national growth trends.
Revenue Impact and Shareholder Value
Management anticipates that this strategic partnership could translate into seven-figure annualized revenues, while simultaneously boosting foot traffic and customer acquisition through reciprocal product placement. The cross-distribution model also mitigates risk by ensuring exposure to two distinct but synergistic consumer bases - dispensary shoppers and CBDL's loyal retail following.
"This LOI is more than just a retail deal - it's a strategic partnership that multiplies opportunities on both ends," stated Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We are not only penetrating one of the strongest cannabis markets in the country, but we're also pioneering a distribution model that enhances shareholder value and sets the stage for exponential growth. We believe this collaboration will be the first of many as we aggressively expand across the East Coast."
Expanding Beyond New Jersey
CBDL views this New Jersey collaboration as a launchpad for broader growth. The Company plans to replicate this model with additional dispensaries and retailers in high-demand markets, creating a scalable blueprint for expansion. By leveraging strong brand equity, product innovation, and investor backing, CBDL is strategically positioned to capture substantial market share as the industry continues its rapid ascent.
About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. (OTC:CBDL) is a publicly traded company focused on the development, marketing, and distribution of CBD-based products and wellness solutions. Through its flagship subsidiary, CBD Vault, the Company offers a comprehensive line of CBD products including tinctures, pain creams, roll-ons, edibles, topicals, beverages, hair and skin care, supplements, and pet formulas. CBDL's mission is to capture market share in the rapidly expanding CBD and cannabis sectors by leveraging retail, e-commerce, and wholesale distribution strategies.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
Website: https://www.thecbdvault.com
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the strategic partnership between CBD Life Sciences (CBDL) and the New Jersey dispensary?
How much revenue is CBDL expecting from the New Jersey dispensary partnership?
What products will CBDL distribute through the New Jersey dispensary?
What is the projected size of New Jersey's cannabis market by 2026?
How does this partnership fit into CBDL's expansion strategy?
